Related Experiment Video
Updated: Jul 3, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Emerging Immune-Based Therapeutic Strategies in Hepatocellular Carcinoma
Janine Kah1,2,3, Werner Dammermann2,3, Stefan Lueth2,3
1Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Summary
Hepatocellular carcinoma (HCC) immunotherapy shows promise but faces challenges due to the complex tumor microenvironment. Novel strategies targeting immune checkpoints and enhancing cell therapies are crucial for improving patient outcomes.
Area of Science:
- Hepatobiliary cancers
- Immunology
- Oncology
Background:
- Hepatocellular carcinoma (HCC) is a major global cancer mortality cause.
- Current immunotherapies, like immune checkpoint inhibitors, offer limited durable responses in HCC patients.
- The tumor microenvironment and liver disease etiology create complex immune suppression, hindering treatment efficacy.
Purpose of the Study:
- To review recent advancements in HCC immunotherapy.
- To discuss emerging immune checkpoint pathways, cellular therapies, and NK cell strategies.
- To highlight the role of liquid biopsies in monitoring and biomarker development for HCC immunotherapy.
Main Methods:
- Literature review of recent HCC immunotherapy research.
- Analysis of immune evasion mechanisms in the HCC tumor microenvironment.
- Discussion of novel therapeutic targets and strategies, including TIGIT, Tim-3, GPC3-targeted therapies, bispecific antibodies, and NK cell therapies.
Main Results:
- Limited efficacy of current immunotherapies is linked to HCC's immune landscape.
- Emerging targets like TIGIT and Tim-3, alongside GPC3-targeted therapies and NK cell strategies, show potential.
- Liquid biopsies offer promise for treatment monitoring and biomarker discovery.
Conclusions:
- Integrated, biomarker-guided therapeutic strategies are essential for improving HCC immunotherapy efficacy.
- Addressing immune suppression within the tumor microenvironment is key.
- Further research into novel targets and personalized approaches is needed.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...